BUFFALO, NY / March 10, 2014 / Cleveland BioLabs (CBLI) will host a live webcast to discuss the results of the fourth quarter 2013, to be held Tuesday, March 11, 2014 at 10:00 AM Eastern Time.
To participate in this event, dial 877-407-9205 domestically, or 201-689-8054 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at http://www.investorcalendar.com/IC/CEPage.asp?ID=172305.
If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=172305 or http://www.investorcalendar.com/, as well as via the Cleveland BioLabs web site (http://www.cbiolabs.com/).
About Cleveland BioLabs
Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging deep mechanistic understanding of the cell death process, apoptosis, to develop a robust pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. The Company's lead compound is being developed as both a radiation countermeasure and a cancer treatment. The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs, Inc., and strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute Australia and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com/.
Release ID: 35569